Repay (NASDAQ:RPAY) versus Hillstream Biopharma (NASDAQ:CNTN) Head to Head Review

Hillstream Biopharma (NASDAQ:CNTN) and Repay (NASDAQ:RPAY) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Hillstream Biopharma and Repay, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
Repay	1	3	3	0	2.29

Repay has a consensus target price of $5.25, suggesting a potential upside of 45.03%. Given Repay’s stronger consensus rating and higher possible upside, analysts plainly believe Repay is more favorable than Hillstream Biopharma.

Insider and Institutional Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 82.7% of Repay shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 12.0% of Repay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Hillstream Biopharma has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Repay has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

Profitability

This table compares Hillstream Biopharma and Repay’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Repay	-49.57%	11.03%	4.28%

Earnings & Valuation

This table compares Hillstream Biopharma and Repay”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92 million	($0.50)	-4.76
Repay	$309.26 million	1.11	-$256.72 million	($2.04)	-1.77

Hillstream Biopharma has higher earnings, but lower revenue than Repay. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Repay, indicating that it is currently the more affordable of the two stocks.

Summary

Repay beats Hillstream Biopharma on 10 of the 13 factors compared between the two stocks.

About Hillstream Biopharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

About Repay

Repay Holdings Corporation, payments technology company, provides integrated payment processing solutions to industry-oriented markets in the United States. It operates through two segments: Consumer Payments and Business Payments. The company's payment processing solutions enable consumers and businesses to make payments using electronic payment methods. It also offers a range of solutions relating to electronic payment methods, including credit and debit card processing, automated clearing house (ACH) processing, e-cash, and digital wallet services; virtual credit card processing, enhanced ACH processing, instant funding, clearing and settlement, and communication solutions; and proprietary payment channels that include Web-based, virtual terminal, online client portal, mobile application, text-to-pay, interactive voice response, and point of sale services. It serves customers primarily operating in the personal loans, automotive loans, receivables management, and business-to-business verticals through direct sales representatives and software integration partners. The company was founded in 2006 and is headquartered in Atlanta, Georgia.